Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).
Yuan-Kai ShiJianqiu WuZhen WangLiling ZhangZhao WangMingzhi ZhangHong CenZhigang PengYufu LiLei FanYe GuoLiping MaJie CuiYuhuan GaoHaiyan YangHongyu ZhangLin WangWeihua ZhangHuilai ZhangLiping XieMing JiangHui ZhouYuerong ShuangHang SuXiaoyan KeChuan JinXin DuXin DuLi LiuYaming XiZheng GeRu FengYang ZhangShengyu ZhouFan XieQian WangPublished in: Journal of hematology & oncology (2021)
This clinical trial was registered at the ClinicalTrials.gov (NCT03502629) on April 18, 2018.